14th EUROPEAN AIDS CONFERENCE

OCTOBER 16 - 19, 2013
BRUSSELS · BELGIUM

FINAL PROGRAMME
SCHEDULE AT A GLANCE
WEDNESDAY, OCTOBER 16, 2013

Bozar (Plenary Hall)  Gold Hall  Copper Hall

07:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30

Silver Hall  Room 211+212  Room 213+215  Room 214+216

07:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00

15th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

EACS Pre-Educational Course

Non-Commercial Satellite Symposium
CHAARM
New HIV Prevention Strategies: The Future of Microbicides

Satellite Symposium
Bristol-Myers Squibb
HIV Cure on Trial: Hype or Hope?

Satellite Symposium
AbbVie
The Evolving HIV Treatment Paradigm

Opening Ceremony
## SCHEDULE AT A GLANCE
### THURSDAY, OCTOBER 17, 2013

<table>
<thead>
<tr>
<th>Bozar (Plenary Hall)</th>
<th>Gold Hall</th>
<th>Copper Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:30</strong></td>
<td>Satellite Symposium MSD</td>
<td></td>
</tr>
<tr>
<td><strong>08:00</strong></td>
<td>Integrate Inhibitors - A Retrospective and a Look Ahead</td>
<td></td>
</tr>
<tr>
<td><strong>08:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>09:00</strong></td>
<td>PL 1 Hepatitis C Treatment - the Revolution</td>
<td></td>
</tr>
<tr>
<td><strong>09:30</strong></td>
<td>PL 2 Inflammation and Cardiovascular Disease</td>
<td></td>
</tr>
<tr>
<td><strong>10:00</strong></td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td>PS 1 Prevention and Management of Co-Morbidities - Joint Session with the 15th International Workshop on Co-Morbidities &amp; Adverse Drug Reactions in HIV</td>
<td>PS 2 Resistance and Immunity  PS 3 ART in Distinct Populations</td>
</tr>
<tr>
<td><strong>11:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:30</strong></td>
<td>Lunch / Poster Session</td>
<td>Special Session on Resource Limited Settings</td>
</tr>
<tr>
<td><strong>13:00</strong></td>
<td></td>
<td>Best Poster Discussion 1  Session Convened by EATG</td>
</tr>
<tr>
<td><strong>13:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td>PS 4 Antiretroviral Therapy I</td>
<td>PS 5 People Living Long Term with HIV  PS 6 Sexually Transmitted Diseases / HPV / Tumors</td>
</tr>
<tr>
<td><strong>14:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16:00</strong></td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td><strong>16:30</strong></td>
<td>Satellite Symposium Gilead</td>
<td></td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td>Rooted in Research: The Future of HIV</td>
<td></td>
</tr>
<tr>
<td><strong>17:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>18:00</strong></td>
<td>Satellite Symposium ViIV Healthcare</td>
<td></td>
</tr>
<tr>
<td><strong>18:30</strong></td>
<td>Just Another HIV Symposium? Think Again...</td>
<td></td>
</tr>
<tr>
<td><strong>19:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>19:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>20:00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>20:30</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Silver Hall</th>
<th>Room 211+212</th>
<th>Room 213+215</th>
<th>Room 214+216</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:30</strong></td>
<td>Meet the Experts HIV-2</td>
<td>Meet the Experts Pregnancy / Paediatrics</td>
<td></td>
</tr>
<tr>
<td><strong>08:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>08:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>09:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>09:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12:30</strong></td>
<td>Lunch / Poster Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16:00</strong></td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td><strong>16:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>17:30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>18:00</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **Yellow**: Plenary Lectures (PL)
- **Light Yellow**: Satellite Symposia
- **Orange**: Pre-Educational Course
- **Blue**: Parallel Sessions (PS)
- **Red**: Ceremonies
- **Gray**: Special Sessions
- **Green**: Meet the Experts
### SCHEDULE AT A GLANCE
**Friday, October 18, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Bozar (Plenary Hall)</th>
<th>Gold Hall</th>
<th>Copper Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>PL 3</strong> The Best of Basic Science for HIV Clinicians in the Last Year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td><strong>PL 4</strong> Controlling the HIV Epidemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>PS 7</strong> Antiretroviral Therapy II</td>
<td><strong>Best Poster Discussion 2</strong></td>
<td><strong>PS 8</strong> Retention in Care / Strategies for HIV Testing</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch / Poster Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>EACS HIV Treatment Guideline: What’s New?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td><strong>PS 9</strong> HIV and Hepatitis Co-Infection</td>
<td><strong>PS 10</strong> EACS / ESCMID Joint Session on Tuberculosis Co-Infection</td>
<td><strong>PS 11</strong> Sex, Drugs and Stigma</td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Satellite Symposium</strong> Bristol-Myers Squibb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>The Evolution of the Standard of Care: The Changing Face of HIV Treatments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td><strong>Satellite Symposium</strong> Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>The HIV Debate: What’s the Best Approach to Personalise Treatment?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Bozar (Plenary Hall)</td>
<td>Gold Hall</td>
<td>Copper Hall</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------</td>
<td>-----------</td>
<td>-------------</td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td><strong>PL 5 HIV and Quality of Care in Europe</strong></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td><strong>PL 6 Antiretroviral Therapy - New Strategies or New Drugs?</strong></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td><strong>Clinical Case Session</strong></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td><strong>ART for Prevention - Roll it Out?</strong></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td><strong>Closing</strong></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
14th EUROPEAN AIDS CONFERENCE

SCHEDULE AT A GLANCE

EACS PRE-EDUCATIONAL COURSE

SCIENTIFIC PROGRAMME

POSTERS

SATELLITE SYMPOSIA

CONFERENCE VENUE

EXHIBITORS AND EXHIBITION FLOOR PLAN

EACS 25TH ANNIVERSARY EVENT

GENERAL INFORMATION A - Z

BRUSSELS

IMPORTANT ADDRESSES
09:45 – 17:00 / Copper Hall

Chairs:
Mike Youle, United Kingdom
Laura Waters, United Kingdom
Mitz Desai, United Kingdom

Introduction
Mike Youle, United Kingdom

Women Living with HIV
2 Clinical Cases
Juan Manuel Tiraboschi, United Kingdom

Key Issues for Women Living with HIV
Nicola Mackie, United Kingdom

Questions
Panel

The Great Mimic
2 Clinical Cases
Cristoph Spinner, Germany

What’s New in Syphilis?
Craig Tipple, United Kingdom

Questions
Panel

Coffee Break

Antiretroviral Toxicity & Management
2 Clinical Cases
Pilleriin Soodla, Finland

ARV Toxicity: Key Issues
Paddy Mallon, Ireland

Questions
Panel

Hepatitis C and the Changing Landscape
2 Clinical Cases
Maximillian Aichelburg, Austria

Hepatitis - The Practicalities
Patrick Ingiliz, Germany

Questions
Panel

Coffee Break

TB, Polypharmacy & Drug Interactions
2 Clinical Cases
Nadia Ahmed, United Kingdom

Pitfalls in Prescribing
Simon Edwards, United Kingdom

Questions
Panel
14th EUROPEAN AIDS CONFERENCE

SCHEDULE AT A GLANCE

EACS PRE-EDUCATIONAL COURSE

SCIENTIFIC PROGRAMME

POSTERS

SATELLITE SYMPOSIA

CONFERENCE VENUE

EXHIBITORS AND EXHIBITION FLOOR PLAN

EACS 25TH ANNIVERSARY EVENT

GENERAL INFORMATION A - Z

BRUSSELS

IMPORTANT ADDRESSES
09:00 – 17:00 / Silver Hall

15th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

EACS Conference attendees are welcome between 14:30 - 16:00 free of charge, (based on seat availability in the Silver Hall).

14:30 – 14:45
Serious clinical outcomes are under-reported in prospective studies of initial antiretroviral therapy in HIV-1-infected adults
Frederick J. Lee, Australia

14:45 – 15:00
Hemoglobin A1c is a poor predictor of fasting glycemia in HIV-infected men with low CD4 count, high mean corpuscular hemoglobin and red cell volume
Laurence Slama, France

15:00 – 15:15
Reversibility of estimated glomerular filtration rate (eGFR) in HIV-infected patients discontinuing tenofovir: The Swiss HIV Cohort Study (SHCS)
Qing Wang, Switzerland

15:15 – 15:30
High prevalence of Anal Human Papilloma Virus infection and related cancer precursors in a contemporary cohort of asymptomatic HIV-infected women
Isabelle Heard, France

15:30 – 16:00
General discussion

EACS Conference attendees may register separately to attend the entire workshop.
For more Information: www.intmedpress.com/comorbidities

17:30 – 19:30 / Bozar (Plenary Hall)

Opening Ceremony

Chairs:
Manuel Battegay, Switzerland
Nathan Clumeck, Belgium

Welcome
Manuel Battegay, Switzerland
Nathan Clumeck, Belgium

Making an Impact on the HIV Epidemic in Eastern Europe and Central Asia
Michel Kazatchkine, UN Secretary General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia, France

HIV in Africa: Looking Back – Looking Forward
Kevin De Cock, Director of the U.S. Centers for Disease Control and Prevention’s (CDC) Center for Global Health, United States

EACS Award Ceremony

How Can The European Community Impact on HIV
Ruxandra Draghia-Akli, Director Health Directorate at the Research DG of the European Commission, Romania

Address
Laurette Onkelinx, Vice Prime Minister, Minister of Social Affairs and Public Health, Belgium

Address
Elio Di Rupo, Prime Minister, Belgium

Welcome Reception
**07:45 – 08:45 / Room 211+212**

**Meet the Experts – HIV-2**
Ricardo Camacho, Portugal
Sophie Matheron, France

**07:45 – 08:45 / Room 213+215**

**Meet the Experts – Pregnancy / Paediatrics**
Marco Floridia, Italy
Jack Levy, Belgium

**09:00 – 09:30 / Bozar (Plenary Hall)**

**Plenary Session - PL1**
Hepatitis C Treatment – The Revolution

Chairs:
Stefan Mauss, Germany
Peter Reiss, Netherlands

Hepatitis C Treatment – The Revolution
Heiner Wedemeyer, Germany

**10:30 – 12:30 / Bozar (Plenary Hall)**

**Parallel Session - PS1**
Prevention and Management of Co-Morbidities – Joint Parallel Session with the 15th International Workshop on Co-Morbidities & Adverse Drug Reactions in HIV

Chairs:
Andrew Carr, Australia
Paddy Mallon, Ireland

ML1: Recent Advances in Prevention and Management of Hepatocellular Carcinoma
Augusto Villanueva, Spain

**PS1/1**
Acute Kidney Injury Caused by Tenofovir Disoproxil Fumarate and Diclofenac Co-administration
M. Bickel¹, P. Khaykin², C. Stephan², K. Schmidt², T. Lutz¹,
P. Gute¹, A. Haberl², H.R. Brodt², O. Jung³
¹Infektiologikum, Frankfurt, Germany, ²HIVCENTER, Goethe University, Infectious Disease, Frankfurt, Germany, ³Goethe University, Nephrology, Frankfurt, Germany

ML2: Recent Advances in Cardiovascular Disease Prevention and Management
Neil Poulter, United Kingdom

**PS1/2**
Greater Arterial Stiffness in Middle-aged HIV-positive Men on cART May be Explained by an Increased Prevalence of Hypertension, Smoking and Systemic Inflammation
K.W. Kooij¹, F. Wit¹, J. Schouten¹², M. van der Valk³,
N. Kootstra⁴, I. Stolte⁵, M. Prins⁶, B.-J. van den Born⁶,
P. Reiss¹³, on behalf of the AGEHIV Cohort Study Group
¹Academic Medical Center and Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam, Netherlands, ²Academic Medical Center, Department of Neurology, Amsterdam, Netherlands, ³Academic Medical Centre, Department of Internal Medicine, Division of Infectious Diseases, Amsterdam, Netherlands, ⁴Academic Medical Centre, Department of Experimental Immunology, Amsterdam, Netherlands, ⁵Public Health Service Amsterdam, Infectious Diseases Research, Amsterdam, Netherlands, ⁶Academic Medical Centre, Department of Vascular Medicine, Amsterdam, Netherlands
PS1/3
An Updated Prediction Model of the Global Risk of Cardiovascular Disease in HIV-positive Persons; The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) Study
D:A:D Study Group
¹Odense University Hospital, Dep Infectious Diseases, Odense, Denmark, ²Rigshospitalet, University of Copenhagen, Faculty of Health Sciences, Copenhagen HIV Programme, Copenhagen, Denmark, ³UCL, Royal Free Campus, Research Department of Infection and Population Health, London, United Kingdom, ⁴University Hospital Zürich, Division of Infectious Diseases and Hospital Epidemiology, Zürich, Switzerland, ⁵University of Amsterdam, Academic Medical Centre, Amsterdam, Netherlands, ⁶Université Victor Segalen Bordeaux 2, Institut de Santé Publique Épidémiologie Développement (ISPED), Bordeaux, France, ⁷St Pierre University Hospital, Dep Infectious Diseases, Brussels, Belgium, ⁸Hospital San Paolo, University of Milan, Dep Infectious Diseases, Milan, Italy, ⁹Centre Hospitalier Universitaire de Nice, Dep Clinical Research and Innovation, Nice, France, ¹⁰The Kirby Institute, University of New South Wales, Biostatistics and Databases Program, Sydney, Australia

ML3: Prevention and Management of Osteoporosis
Todd Brown, United States

PS1/4
Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults
L. Battalora¹, K. Buchacz², C. Armon³, E.T. Overton⁴, J. Hammer⁵, J.S. Chmiel⁶, T.J. Bush⁷, J.T. Brooks⁸, B. Young⁹, HIV Outpatient Study and SUN Study Investigators
¹Colorado School of Mines, Golden, United States, ²Centers for Disease Control and Prevention, Atlanta, United States, ³Cerner Corporation, Vienna, United States, ⁴University of Alabama, Birmingham, United States, ⁵Denver Infectious Disease Consultants, Denver, United States, ⁶Feinberg School of Medicine, Northwestern University, Chicago, United States, ⁷APEX Family Medicine, Denver, United States, ⁸International Association of Providers of AIDS Care, Washington DC, United States
**PS2/2**

Prevalence of Detected Drug Resistance across Different Regions of Europe: Data from EuroSIDA 1997-2012

A. Schultze¹, A.N. Phillips¹, R. Paredes², M. Battegay³, J. Rockstroh⁴, L. Machala⁵, J. Tomazic⁶, O. Kirk⁷,⁸, J.D. Lundgren⁷,⁸, A. Cozzi-Lepri¹, EuroSIDA in EuroCOORD

¹University College London (UCL), Research Department of Infection and Population Health, London, United Kingdom, ²Fundacions IrisiCaixa i Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain, ³University Hospital Basel, Basel, Switzerland, ⁴Universitäts Klinik Bonn, Bonn, Germany, ⁵University Hospital Bulovka, Faculty Hospital Bulovka, Faculty Hospital Bulovka, Czech Republic, ⁶University Clinical Centre Ljubljana, Ljubljana, Slovenia, ⁷Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Copenhagen HIV Program, University of Copenhagen, Copenhagen, Denmark

**PS2/3**

Association between Age and Long-term CD4 Cell Count Trajectory in HIV-1 Infected Individuals with Sustained Viral Suppression Depends on CD4 Cell Count at Start cART

L. Gras¹, A. Kesselring¹, S. van Lelyveld², K. Brinkman³, J.M. Prins⁴,⁵, P. Reiss¹,⁶, on behalf of the Netherlands ATHENA Observational HIV Cohort

¹Stichting HIV Monitoring, Amsterdam, Netherlands, ²University Medical Centre Utrecht, Department of Internal Medicine and Infectious Diseases, Utrecht, Netherlands, ³Onze Lieve Vrouwe Gasthuis, Department of Internal Medicine, Amsterdam, Netherlands, ⁴Academic Medical Centre of the University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands, ⁵Academic Medical Centre of the University of Amsterdam, Centre for Infection and Immunity Amsterdam (CINIMA), Amsterdam, Netherlands, ⁶Academic Medical Centre of the University of Amsterdam, Amsterdam, Netherlands

**PS2/4**

Four-year Longitudinal Follow-up of Serologic Responses to Primary Vaccination with One Dose or Two Doses of 7-valent Pneumococcal Conjugate Vaccine in HIV-infected Patients in the Era of Combination Antiretroviral Therapy

Y.-C. Su¹, C.-C. Hung², W.-C. Liu¹, B.-R. Wu¹, S.-Y. Chang²

¹National Taiwan University Hospital, Taipei, Taiwan, Republic of China, ²National Taiwan University, Taipei, Taiwan, Republic of China

**PS2/5**

Synergistic Activation of HIV-1 Expression by Compounds Targeting the Positive Transcription Elongation Factor b (PTEF-b) and by Inducers of the NF-κB Signaling Pathway

G. Darcis¹, A. Kula², S. Bouchat², K. Kabeya³, N. Delacourt², C. Vanhulle², J.-S. Gatot¹, D. Vaira², A. Burny², G. Herbein², N. Clumeck¹, O. Rohr², M. Moutschen², C. Rouzioux², S. De Wit³, C. Van Lint¹⁰

¹Université de Liège, CHU de Liège, Liège, Belgium, ²Université Libre de Bruxelles ULB, Bruxelles, Belgium, ³Service des Maladies Infectieuses, CHU St-Pierre, ULB, Bruxelles, Belgium, ⁴AIDS Reference Center, ULg, Liège, Belgium, ⁵Institut de Biologie et de Médecine Moléculaire, ULB, Bruxelles/Gosselies, Belgium, ⁶Department of Adult's Infectious Diseases, Medical University of Warsaw Virology, Franche-Comte University, Besançon, France, ⁷Virology Institute, INSERM, Strasbourg, France, ⁸Service des Maladies Infectieuses, CHU Liège, ULg, Liège, Belgium, ⁹Service de Virologie, EA 3620, Université Paris-Descartes, Paris, France, ¹⁰Laboratory of Molecular Virology, Institut de Biologie et de Médecine Moléculaire IBMM, ULB * GD and AK Equally Contribute to this Work, Gosselies, Belgium

AIDS Reference Centre, University of Ljubljana, Ljubljana, Slovenia, ²University of Vienna, Vienna, Austria, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Slovak Medical University, Bratislava, Slovakia, ⁵University of Belgrade, Faculty of Medicine, Belgrade, Serbia, ²⁶University Hospital for Infectious Diseases ‘Dr Fran Mihaljevic’, Zagreb, Croatia, ²⁷University Medical Center Utrecht, Utrecht, Netherlands
10:30 – 12:30 / Copper Hall

Parallel Session - PS3
ART in Distinct Populations

Chairs:
Antonella d’Arminio Monforte, Milano, Italy
Mike Youle, United Kingdom

ML1: HIV/AIDS Prevention and Treatment in Trans and Other Distinct Populations
Judit Takacs, Hungary

PS3/1
Viral Load Dynamics in HIV-infected Women after HAART Termination at Delivery
E.A. Orlova-Morozova1, G.D. Kaminskiy1, A.J. Pronin1,
G.O. Gudima2, I.G. Sidorovich2, R.M. Khaitov2
1Moscow Regional AIDS Centre, Moscow, Russian Federation, 2Institute of Immunology, Moscow, Russian Federation

PS3/2
Long-term Response to Combination Antiretroviral Therapy in HIV-infected Children in the Netherlands Registered from 1996-2012
S. Cohen1, C. Smit2, A.M.C. van Rossum3, P.L.A. Fraaij3,4,
T.F.W. Wolfs5, S.P.M. Geelen5, E.H. Schövinck5, A. Warris5,
H.J. Scherpber1, D. Pajkrt1, Dutch Paediatric HIV Study Group
1Emma Children’s Hospital AMC, Department of Paediatric Infectious Diseases, Amsterdam, Netherlands, 2HIV Monitoring Foundation, Amsterdam, Netherlands,
3Sophia Children’s Hospital, ErasmusMC, Department of Paediatrics, Rotterdam, Netherlands, 4ErasmusMC, Viroscience Lab, Rotterdam, Netherlands, 5Wilhelmina Children’s Hospital, Department of Paediatrics, Utrecht, Netherlands,
6University of Groningen, University Medical Centre, Department of Paediatrics, Groningen, Netherlands, 7Radboud University Medical Centre, Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, Netherlands

PS3/3
Obese HIV-infected Patients Treated with Efavirenz-containing Regimens Are at Risk of Virological Failure: Evidence from COHERE, a Large European Observational Cohort Collaboration
C. Marzolini1, on behalf of the Efavirenz and Obesity Project Team of COHERE in EuroCoord
1University Hospital Basel, Basel, Switzerland

PS3/4
Determinants of Healthcare Costs of HIV Infected Drug Users in Ireland
S. Surah1, A. O’Connor1, S. Keating1,2, K. Hunter1, E. Keenan2,
F. Mulcahy1, C. Walsh3, L. Tilson4, M. Barry5, F. Lyons4
1St James’s Hospital, Guide Clinic, Dublin, Ireland, 2The National Drug Treatment Centre, Dublin, Ireland, 3Trinity College, University of Dublin, Department of Statistics, Dublin, Ireland, 4St James’s Hospital, National Centre for Pharmacoeconomics, Dublin, Ireland

PS3/5
Impact of Novel and Known Allelic CYP2B6 Variants on Efavirenz and Nevirapine Plasma Concentrations and their Metabolites in Antiretroviral Therapy – Treated Patients from Rwanda
A. Gras1, C. Lambert1, G. Iserentant1, K. Iranyumviye2,
O. Collignon3, C. Masquelier1, S. Schneider1, K. Klein5,
J.-C. Karasi2, J.-C. Schmit1, U. Zanger5, C. Devaux1
1CRP-Santé, Laboratory of Retrovirology, Luxembourg, Luxembourg, 2Rwandese Biomedical Center, National Reference Laboratory, Kigali, Rwanda, 3CRP-Santé, Competence Center in Methodology and Statistics, Strassen, Luxembourg,
4National Health Laboratory, Laboratory of Toxicology, Luxembourg, Luxembourg, 5Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

ML2: Drug Drug Interactions
Catia Marzolini, Switzerland
12:30 – 13:00 / Gold Hall

**Special Session**

Special Session on Resource Limited Settings

**Chair:**
Alexandra Calmy, Switzerland

**ML1: Which Standard of Care for Africa?**
Serge Eholié, Côte d’Ivoire

**ML2: Specific Challenges of the HIV Epidemic in Romania**
Adrian Streinu-Cercel, Romania

13:00 – 14:00 / Gold Hall

**Special Session**

Best Poster Discussion 1

**Chairs:**
Andrea Antinori, Italy
Annemarie Wensing, Netherlands

**BPD1/1**

Effect of Immune Activation and Proinflammatory Signalling Pathway Activation on HIV Acquisition in a Cohort of Highly Exposed Commercial Sex Workers in Nairobi

**Y. Keynan**¹, J. Sainsbury², A. Trajtman³, P.J. Mclaren³,
L. Mckinnon⁴, C. Wachihi⁴, J. Kimani⁴

¹University of Manitoba, Internal Medicine, Medical Microbiology and Community Health Sciences, Winnipeg, Canada, ²University of Manitoba, Winnipeg, Canada, ³Institute of Microbiology, Lausanne, Switzerland, ⁴University of Nairobi, Nairobi, Kenya

**BPD1/2**

Vitamin D Level in HIV-infected Persons: Prognostic Value for All-cause Death, and Association with Inflammatory Markers, Results from the EuroSIDA Cohort Study

**J.P. Viard**¹, L. Shepherd², J.C. Souberbielle³, J.P. Bastard⁴, S. Fellahi⁴, J. Capeau⁴, J. Reekie⁷, P. Reiss⁸, O. Kirk⁹, J. Lundgren¹⁰, A. Mocroft¹¹, EuroSIDA in EuroCOORD

¹Université Paris Descartes, Centre de Diagnostic et de Thérapeutique, Hôpital-Dieu, APHP, and EA 3620, Paris, France, ²University College London, London, United Kingdom, ³Hôpital Necker, Service d’Explorations Fonctionnelles, Paris, France, ⁴Hôpital Tenon, Unit of Biochemistry, Paris, France, ⁵Faculté de Médecine Saint Antoine, INSERM, UMR_S 938, Paris, France, ⁶UMR_S 938, UPMC Univ Paris 06, Paris, France, ⁷University of New South Wales, The Kirby Institute, Sydney, Australia, ⁸University of Amsterdam, Academic Medical Centre (AMC), Amsterdam, Netherlands, ⁹University of Copenhagen, Copenhagen HIV Programme, Copenhagen, Denmark, ¹⁰Rigshospitalet, Department of Infectious Diseases, Copenhagen, Denmark, ¹¹University College London, Department of Infection and Population Health, London, United Kingdom

**BPD1/3**

Vitamin D Homeostasis and Tenofovir Induced Proximal Tubulopathy in HIV Patients

**W. van der Heijden**¹, D. Burger², F. Sweep³, P. Koopmans¹, A. van der Ven¹

¹Radboud University Medical Centre, Department of Internal Medicine, Division Infectious Diseases, Nijmegen, Netherlands, ²Radboud University Medical Centre, Department of Pharmacy, Nijmegen, Netherlands, ³Radboud University Medical Centre, Department of Clinical Chemistry, Nijmegen, Netherlands

**BPD1/4**

Reduced Bone Mineral Density (BMD) is Largely Explained by Lower Body Weight in HIV-positive Individuals and More Pronounced in Younger Men Having Sex with Men (MSM), Regardless of HIV-status

**K.W. Kooij**¹, F.W. Wit¹, P.H. Bisschop², J. Schouten¹, I. Stolte⁴, M. Prins³, M. van der Valk⁵, B.L. van Eck-Smit⁶, P. Lips⁷, P. Reiss¹, on behalf of the AGEhIV Cohort Study Group

¹Academic Medical Center and Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam, Netherlands, ²Academic Medical Center, Department of Endocrinology and Metabolism, Amsterdam, Netherlands, ³Academic Medical Center, Department of Neurology, Amsterdam, Netherlands, ⁴Public Health Service Amsterdam, Infectious Diseases Research, Amsterdam, Netherlands, ⁵Academic Medical Centre, Department of Internal Medicine, Division of Infectious Diseases, Amsterdam, Netherlands, ⁶Academic Medical Center, Department of Nuclear Medicine, Amsterdam, Netherlands, ⁷VU University Medical Center, Department of Internal Medicine/Endocrinology, Amsterdam, Netherlands
BPD1/5
Cardiovascular Disease Framingham Risk Score (FRS) and VACS Index Are Associated with Neurocognitive Impairment (NCI) in HIV-positive Patients
C. Pinnetti1, P. Balestra1, R. Libertone1, P. Lorenzini1, M. Ricottini1, M.M. Piazza1, S. Menichetti1, V. Tozzi1, A. Antinori1, A. Ammassari1
1National Institute for Infectious Diseases ‘Spallanzani’, Rome, Italy

BPD1/6
The Characteristics of NRTI and NNRTI Resistance-associated Mutations (RAMs) in Patients with HIV-1 CRF01_AE Subtype who Failed Nevirapine and Efavirenz-containing Regimens
O. Putcharoen1, S. Sirivichayakul2, A. Mekprasen2, P. Teeranaipong3, K. Ruxrungtham4
1Division of Infectious Diseases, King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Medicine, Bangkok, Thailand, 2Division of Allergy and Clinical Immunology, Chulalongkorn University, Medicine, Bangkok, Thailand, 3King Chulalongkorn Memorial Hospital, Department of Medicine, Bangkok, Thailand, 4Division of Allergy and Clinical Immunology, Chulalongkorn University, Bangkok, Thailand

BPD1/7
Efficacy of Raltegravir Once Daily in Switching Strategies in HIV-1 Infected Patients with Suppressed Viraemia
F. Caby1, M. Bonmarchand2, C. Soulie3, G. Peytavin4, R. Agher1, B. Revollo5, C. Delanoe6, R. Tubiana7, M.-A. Valantin8, A.-G. Marcelin9, C. Katlama5
1Hôpital Pitié-Salpêtrière, Infectious Diseases, Paris, France, 2Hôpital Pitié-Salpêtrière, Internal Medicine, Paris, France, 3Hôpital Pitié-Salpêtrière, Virology, Paris, France, 4Hôpital Bichat Claude Bernard, Pharmacology, Paris, France, 5Hôpital Pitié-Salpêtrière, Paris, France

13:00 – 14:00 / Copper Hall

Special Session
Standards of HIV Care in Europe After the Crisis - The Way Forward
Convened by EATG (European AIDS Treatment Group)

Chairs:
Antonella d’Arminio Monforte, Milano, Italy
Brian West, United Kingdom

Speaker:
Tamás Bereczky, Belgium

13:00 – 14:00 / Silver Hall

EACS General Assembly

14:00 – 16:00 / Bozar (Plenary Hall)

Parallel Session - PS4
Antiretroviral Therapy I

Chairs:
Stéphane De Wit, Belgium
Christine Katlama, France

ML1: Population-level Impact of ART in a rural, high prevalence setting
Marie-Louise Newell, United Kingdom

PS4/1
Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine/Tenofovir (FTC/TDF), in Treatment-naïve HIV-1-infected Adults with CCR5-Tropic Virus
1University of Cincinnati, Cincinnati, United States, 2aIDS research Consortium of Atlanta, Atlanta, United States, 3Nevada AIDS Research and Education Society, Las Vegas, United States, 4Orlando Immunology Center, Orlando, United States, 5Therapeutic Concepts, Houston, United States, 6Quest Clinical Research, San Francisco, United States, 7Pacific Oaks Medical Group, Beverly Hills, United States, 8University of Alabama at Birmingham, Birmingham, United States, 9Tobira Therapeutics, Inc., San Francisco, United States

PS4/2
48-weeks Outcomes of Atazanavir/ritonavir Monotherapy as Maintenance Strategy in HIV-1 Treated Subjects with Viral Suppression: Interim Analysis Results of the MODAT Study (NCT01511809)
A. Castagna1, V. Spagnuolo1,2, L. Galli1, C. Vinci1, S. Nozza1, E. Carini1, A. D’Arminio Monforte3, F. Montella4, A. Antinori5, A. Di Biagio6, S. Rusconi7, A. Lazzarin1,2
1San Raffaele Scientific Institute, Milan, Italy, 2Università Vita-Salute San
PS4/3
Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) + Nevirapine (NVP) to TDF/FTC/Rilpivirine Single Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Subjects: 24 Weeks Outcome
C. Allavena1, E. Dailly2, V. Reliquet1, S. Sécher3, E. André-Garnier4, R. Bouquié2, B. Bonnet1, H. Hüb3, F. Raffi1
1CHU Nantes, Infectious Diseases, Nantes, France, 2CHU Nantes, Pharmacology, Nantes, France, 3CHU Nantes, COREVIH Pays de la Loire, Nantes, France, 4CHU Nantes, Virology, Nantes, France

PS4/4
Increased Risk of Virological Failure with Lamivudine Compared to Emtricitabine in Tenofovir and Nevirapine Containing Antiretroviral Therapy
C. Rokx1, A. Fibrani2, D.A.M. van de Vijver2, M. Schutten2, A. Verbon1, B.J.A. Rijn1
1Erasmus MC, Internal Medicine, Rotterdam, Netherlands, 2Erasmus MC, Virology, Rotterdam, Netherlands

PS4/5
Effect of Once-daily Dosing and Lower Pill Burden Antiretroviral Regimens for HIV Infection: A Meta-analysis of Randomised Controlled Trials
1Pittsburgh University, Infectious Diseases Epidemiology, Pittsburgh, United States, 2Johns Hopkins University, Epidemiology and International Health, Baltimore, United States, 3Côte de Nacre University, Department of Biostatistics and Clinical Research, Côte de Nacre Teaching Hospital, Caen, France, 4Centre for Applied Health Research and Delivery, Warwick Medical School, University of Warwick, Coventry, United Kingdom, 5Liverpool School of Tropical Medicine, International Health Group, Liverpool, United Kingdom, 6University of Pennsylvania, Perelman School of Medicine, Department of Medicine, Philadelphia, United States, 7Johns Hopkins Bloomberg School of Public Health, Epidemiology, Baltimore, United States, 8Harvard Medical School, Brigham and Women’s Hospital, Boston, United States, 9Johns Hopkins University, School of Medicine, Baltimore, United States, 10University of Alabama, Department of Medicine, Alabama, United States, 11University of Ottawa, Ottawa, Canada, 12Baylor College of Medicine, Department of Medicine, Houston, United States

LBPS4/6
Once-daily Dolutegravir versus Darunavir/Ritonavir in Antiretroviral Naive Subjects: 48 Week Subgroup Analyses from FLAMINGO
B. Clotet1, M.-A. Khuong2, A. Antinori3, J. van Lunzen4, I. Dumitrut5, V. Pokrovskiy6, J. Fehr7, R. Ortiz8, M. Saag9, J. Feinberg10, J. Harris11, C. Brennan12, S. Min12, R. Cuffe13
1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hôpital Delafontaine, Saint-Denis, France, 3Istituto Nazionale Malattie Infettive, Roma, Italy, 4Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, 5Clinical Infectious Diseases Hospital Constanta, Constanta, Romania, 6Central Research Institute for Epidemiology of Rospotrebndazor, Moscow, Russian Federation, 7Universität Zürich, Zurich, Switzerland, 8Orlando Immunology Center, Orlando, United States, 9University of Alabama, Birmingham, United States, 10University College of Medicine, Cincinnati, United States, 11GlaxoSmithKline, Brentford, United Kingdom, 12GlaxoSmithKline, RTP, United States, 13ViiV Healthcare, Brentford, United Kingdom

ML2: Generic ART in Europe
Jose Maria Llibre, Spain

14:00 – 16:00 / Gold Hall
Parallel Session - PS5
People Living Long Term with HIV

Chairs:
Kamal Mansinho, Portugal
Antonios Papadopoulos, Greece

ML1: Chronic Kidney Disease in HIV
Lene Ryom, Denmark

PS5/1
The Spectrum of Clinical Disease in HIV-positive Persons and Relationship with Markers of Deteriorating Renal Function
A. Mocroft1, L. Ryom2,3, J. Begovac4, A. D’Arminio Monforte5, A. Vassilenko6, J. Gatell7, E. Florence8, V. Ormaasen9, O. Kirk2,3,
SCIENTIFIC PROGRAMME
THURSDAY, OCTOBER 17, 2013

J. Lundgren2,3, EuroSIDA in EuroCOORD
1University College London, London, United Kingdom, 2Copenhagen HIV Program, Copenhagen, Denmark, 3Copenhagen University Hospital/Rigshospitalet, Department of Infectious Disease, Copenhagen, Denmark, 4University Hospital of Infectious Diseases, Zagreb, Croatia, 5Institute of Infectious Diseases, Department of Health Sciences, Milan, Italy, 6Belarus State Medical University, Minsk, Belarus, 7Hospital Clinic i Provincial, Barcelona, Spain, 8Institute of Tropical Medicine, Antwerp, Belgium, 9Ullevål University Hospital, Ullevål, Norway

PS5/2
Response to Combination Antiretroviral Treatment in HIV Positive Individuals in Europe: Variation by Educational Level
S. Lodi1, COHERE in EuroCoord
1Instituto de Salud Carlos III, Madrid, Spain

PS5/3
Declining Suicide rates among People Leaving with HIV (PLHIV) Initiating HAART between August 1996 – June 2012 in the HAART Observational Medical Evaluation and Research Cohort in British Columbia, Canada
J. Gurm1, S. Guillemi1, E. Ding1, V. Strethlau2, J.S.G. Montaner1,2, R.S. Hogg1,4
1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada, 2University of British Columbia, Department of Psychiatry, Vancouver, Canada, 3University of British Columbia, Faculty of Medicine, Vancouver, Canada, 4Simon Fraser University, Faculty of Health Sciences, Burnaby, Canada

PS5/4
Utilization of Psychotropic Drugs Prescribed to Persons with and without HIV Infection; A Danish Nationwide Population-based Cohort Study
L.D. Rasmussen1, D. Obel2, G. Kronborg3, C.S. Larsen4, C. Pedersen5, J. Gerstoft6, N. Obel7
1University of Southern Denmark and Odense University Hospital, Department of Infectious Diseases, Odense, Denmark, 2Private Clinic of Child and Adolescent Psychiatry, Aarhus, Denmark, 3Copenhagen University Hospital, Department of Infectious Diseases, Hvidovre, Denmark, 4Aarhus University Hospital Skejby, Department of Infectious Diseases, Aarhus, Denmark, 5Odense University Hospital, Department of Infectious Diseases, Odense, Denmark, 6Copenhagen University Hospital, Rigshospital, Department of Infectious Diseases, Copenhagen, Denmark, 7Copenhagen University Hospital, Hvidovre University Hospital, Rigshospital, Department of Infectious Diseases, Copenhagen, Denmark

PS5/5
Mortality in Migrants Living with HIV in Western Europe: Differences by Geographical Origin and Gender
S. Monge1, on behalf of COHERE in EuroCoord
1Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain

PS5/6
Care Pathways of Patients Infected with HIV in France
C. Jacomet1, F. Peyrol2, L. Cormerais3, M. Guiguet4, A. Simon5, P. Berland6, D. Rey7, L. Gerbaud2
1Hôpital Gabriel Montpied, Maladies Infectieuses et Tropicales, Clermont Ferrand, France, 2CHU Clermont Ferrand, Service de Santé Publique, Clermont Ferrand, France, 3Hôpital Gabriel Montpied, Service des Maladies Infectieuses et Tropicales, Clermont Ferrand, France, 4INSERM U 943, UMPC Univ Paris 06, UMR S 943, Epidemiologie, Paris, France, 5Hôpital La Pitié Salpêtrière, Médecine Interne, Paris, France, 6CHU Clermont Ferrand, Service de Santé Publique, Clermont-Ferrand, France, 7Nouvel Hôpital Civil, Le Trait d’Union, Strasbourg, France

14:00 – 16:00 / Copper Hall
Parallel Session - PS6
Sexually Transmitted Diseases / HPV / Tumors

Chairs:
Gerd Fätkenheuer, Germany
Fiona Mulcahy, Ireland

ML1: How to Manage Syphilis in HIV
Martin Fisher, United Kingdom

PS6/1
Diagnosis of Neurosyphilis in People Living with HIV Infection (PLHIV): Is Lumbar Puncture Advocated Beyond CNS Symptoms?
K. Protopapas1, I. Katsarolis1, D. Kavatha1, A. Ikonomou1, A. Papadopoulos1, A. Antoniadou1
1ATTIKON University Hospital, 4th Dept of Internal Medicine, Haidari, Athens, Greece
PS6/2
Prospective Observational European Study of the Natural History and Treatment of Syphilis in HIV Positive Individuals – The POETS Study
D.F. Rowley¹, G. Fätkenheuer², P. Święcki³, A. Horban³, R. Zangerle⁴, C. Sabin⁵, S. O’Dea¹, F. Mulcahy¹
¹St James’ Hospital, The Guide Clinic, Dublin, Ireland, ²Klinik für Innere Medizin, Uniklinik Köln, Köln, Germany, ³Hospital for Infectious Diseases, Warsaw, Poland, ⁴Department of Dermatology and Venereology, Innsbruck Medical University, Innsbruck, Austria, ⁵Royal Free Campus, London, United Kingdom

PS6/3
High Prevalence of Anal Dysplasia in a Cohort of HIV Positive MSM Enrolled in a Systematic Screening Program: Risk Factors and Impact of cART
A. Libois¹, F. Feoli², M. Nkuize³, M. Delforge¹, S. De Wit¹, N. Clumeck¹
¹CHU Saint-Pierre, Infectious Diseases, Brussels, Belgium, ²CHU Saint-Pierre, Laboratory of Pathology, Brussels, Belgium, ³CHU Saint-Pierre, Gastro Enteroenterology, Brussels, Belgium

PS6/4
High Prevalence of Anal Human Papilloma Virus Infection and Related Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-infected Women
I. Heard¹,²,³, I. Etienney⁴, V. Potard³, I. Poizot-Martin⁵,⁶, C. Moore⁷, A.-C. Lesage⁴, E. Ressiot⁵, C. Crenn-Hebert⁶, J.-F. Flejou⁷, H. Cubie⁷, T. Darragh¹⁰, D. Costagniola³, ANRS-C017 VIHGY Study Group
¹Pasteur Institute, National HPV Reference Laboratory, Paris, France, ²Groupe Hospitalier Pitie-Salpêtrière, Paris, France, ³INSERM U 943, UMPC Univ Paris 06, UMR S 943, Paris, France, ⁴Groupe Hospitalier Diaconesses - Croix Saint-Simon, Paris, France, ⁵APHM Sainte-Marguerite, Service d’Immunohématologie Clinique, Marseille, France, ⁶Inserm U 912 (SESSTIM), Marseille, France, ⁷Scottish HPV Reference Laboratory, Edinburgh, United Kingdom, ⁸Gynaecology Department, APHP-HUPNVS, Colombes, France, ⁹Hôpital Saint-Antoine, Department of Pathology, Paris, France, ¹⁰UCSF, Department of Pathology, San Francisco, United States

PS6/5
Infection Related and Unrelated Malignancies, HIV and the Aging Population
L. Shepherd¹, A. Borges²,³, B. Ledergerber¹, P. Domingo⁵, J. Rockstroh⁶, B. Knysz⁷, O. Kirk²,³, A. Mocroft¹, J. Lundgren²,³, EuroSIDA in EuroCOORD
¹University College London, Department of Infection and Population Health, London, United Kingdom, ²Rigshospitalet, Department of Infectious Diseases, Copenhagen, Denmark, ³University of Copenhagen, Copenhagen HIV Programme, Copenhagen, Denmark, ⁴University Hospital, Division of Infectious Diseases, Zurich, Switzerland, ⁵Hospital Sant Pau, Barcelona, Spain, ⁶University Hospital Bonn, Department of Medicine I, Bonn, Germany, ⁷Wroclaw University, Department of Infectious Diseases, Wroclaw, Poland

PS6/6
Efavirenz Shows a Selective Cytotoxicity against Cancer Cells which is Strengthened by Cannabinoids
M. Hecht¹, T. Harrer², M. Böttner³, M. Schwengler¹, S. Erber¹, R. Fietkau¹, L.V. Distel¹
¹University Hospital Erlangen, Radiation Oncology, Erlangen, Germany, ²University Hospital Erlangen, Internal Medicine 3, Erlangen, Germany, ³University Hospital Erlangen, Pathology, Erlangen, Germany

ML2: HPV-Associated Malignancies in HIV
Olivier Richel, Netherlands
**Meet the Experts – Update on IRIS & OIs**
**IRIS / OI Situation**
Emili Letang, Spain
Michel Moutschen, Belgium

**Meet the Experts – Tools for the Management of Osteoporosis**
**Tools for Management of Osteoporosis**
Markus Bickel, Germany
Aoife Cotter, Ireland

**Meet the Experts – Neurocognition**
**Neurocognition**
Magnus Gisslen, Sweden
Carlo Torti, Italy

**Plenary Session - PL3**
The Best of Basic Science for HIV Clinicians in the Last Year

Chairs:
Carine Van Lint, Belgium
Carlo Federico Perno, Italy
The Best of Basic Science for HIV Clinicians in the Last Year
Seger Debyser, Belgium

**Plenary Session - PL4**
Controlling the HIV Epidemic

Chairs:
Carlo Federico Perno, Italy
Carine Van Lint, Belgium
Controlling the HIV Epidemic
Caroline Sabin, United Kingdom

**Parallel Session - PS7**
Antiretroviral Therapy II

Chairs:
Jose Gatell, Spain
Cristina Mussini, Italy
ML1: How to Target HIV with Nanomedicine
Andrew Owen, United Kingdom

**PS7/1**
Once-daily Oral GSK1265744 (GSK744) as Part of Combination Therapy in Antiretroviral Naïve Adults: 24-week Safety and Efficacy Results from the LATTE Study (LAI116482)
D. Margolis1, L. Bhatti2, G. Smith3, W. Weinberg4, C. Brinson5, T. Mills6, E. Dejesus7, B. Stancil1, P. Wannamaker1, M. Bomar7, M. St Clair7, W. Spreen1, J. Goodrich8
1GSK, RTP, United States, 2AIDS Healthcare Foundation, Beverly Hills, United States, 3Maple Leaf Medical Clinic, Toronto, Canada, 4Kaiser Permanente, Atlanta, United States, 5Central Texas Clinical Research, Austin, United States, 6HIV Clinic, Los Angeles, United States, 7Orlando Immunology Center, Orlando, United States, 8ViiV Healthcare, RTP, United States
**LBPS7/2**

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir plus Emtricitabine/Tenofovir DF at Week 144 in Treatment-naive HIV-1 Infected Patients

N. Clumeck¹, J.-M. Molina², K. Henry³, J. Gathe⁴, J. Rockstroh⁵, E. DeJesus⁶, X. Wei⁷, K. White⁷, M. Fordyce⁷, M. Rhee⁷, J. Szwarcburg⁷

¹Maladies Infectieuses, Brussels, Belgium, ²Service de Maladies Infectieuses, Paris, France, ³Hennepin County Medical Center, Minneapolis, United States, ⁴Therapeutic Concepts, Houston, United States, ⁵Department of Medicine, University of Bonn, Bonn, Germany, ⁶Orlando Immunology Center, Orlando, United States, ⁷Gilead, Foster City, United States

**PS7/3**

The Impact of Baseline Viral Load (VL) and Time to Viral Suppression on Treatment Responses to First-line Combination Antiretroviral Therapy (cART)

S. Jose¹, L.J. Waters², S. Edwards², P. Benn², C. Sabin¹, UK CHIC

¹UCL Research Department of Infection and Population Health, London, United Kingdom, ²Pimlico Market Centre, London, United Kingdom

**PS7/4**

Level of HIV Viremia below 50 Copies/ml Predicts Virologic Rebound in HAART-treated Patients

A. Calcagno¹, V. Ghisetti², S. Lo Re¹, I. Motta¹, T. Allice², L. Marino¹, M.C. Tettoni¹, L. Trentini¹, C. Bramato¹, G. Orofino³, M. Bonasso¹, B. Salassa¹, G. Di Perri¹, S. Bonora¹

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy, ³Unit of Infectious Diseases, Divisione A, Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy

**PS7/5**

Changes in Bone Turnover Markers and Association with Decreased Total Bone Mineral Density (tBMD) in Treatment-naive Subjects Taking Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC)

T. Brown¹, L. Fredrick², D. Warren², L.K. Toh², B. Renjifo², R. Trinh², R. Qaqish²

¹Johns Hopkins University, Baltimore, United States, ²Abbvie Inc., North Chicago, United States

**LBPS7/6**

Dual Therapy with Lopinavir/Ritonavir (LPV/r) and Lamivudine (3TC) is Non-inferior to Standard Triple Drug Therapy in Naïve HIV-1 Infected Subjects: 48-week Results of the GARDEL Study

P. Cahn¹, The GARDEL Study Group

¹Fundacion Huesped, Clinical Research, Buenos Aires, Argentina

ML2: How to Best Secure Long-term Adherence

Adriana Ammassari, Italy

**BPD2/1**

High Resolution Anoscopy Screening of HIV Positive MSM: Longitudinal Results from a Pilot Study

A. Dalla Pria¹, M. Alfa-Wali², C. Coyle¹, P. Holmes³, P. Fox³, N. Francis¹, M. Nelson³, M. Bower¹

¹Chelsea and Westminster Hospital, National Centre for HIV Malignancy, London, United Kingdom, ²Chelsea and Westminster Hospital, General Surgery, London, United Kingdom, ³Chelsea and Westminster Hospital, HIV/GUM Medicine, London, United Kingdom, ⁴Imperial College, Histopathology, London, United Kingdom

**BPD2/2**

Neurosyphilis in HIV-positive Patients Diagnosed with Early Syphilis

E. Firlag – Burckacka¹, P. Swiecki¹, I. Cielniak¹, E. Siwak¹, J. Gizinska¹, E. Bakowska¹, J. Kubicka¹, J. Kowalski¹, R. Podlasin¹, A. Horban²

¹Hospital of Infectious Diseases, AIDS Diagnosis & Therapy Center, Warsaw, Poland, ²Medical University of Warsaw, Warsaw, Poland
BPD2/3
Predictors of Sustained Virological Response Rates in the Treatment of Acute HCV Infection in HIV Co-infection
C. Boesecke¹, P. Ingiliz², H.-J. Stellbrink³, M. Nelson⁴, E. Page⁵, S. Bhagani⁶, M.-A. Valantin⁷, T. Reiberger⁸, M. Vogel¹, J.K. Rockstroh¹, for the NEAT Study Group
¹Universitätsklinikum Bonn, Medizinische Klinik I, Bonn, Germany, ²MiB, Berlin, Germany, ³ICH Study Center, Hamburg, Germany, ⁴Chelsea and Westminster Hospital, London, United Kingdom, ⁵Royal Free Hospital, London, United Kingdom, ⁶AP-HP, Hôpital La Pitié Salpètrière, Paris, France, ⁷Medical University of Vienna, Vienna, Austria

BPD2/4
Triple Therapy with Telaprevir (TPV) or Boceprevir (BOC) in Cirrhotic HIV/HCV Infected Patients: Real Life On-treatment Data from Europe
P. Mailhes¹, K. Lacombe², J.E. Arends³, M. Puoti⁴, E. Rosenthal⁵, P. Morlat⁶, S. Dominguez⁷, M.A. Valantin⁸, C. Gilbert⁹, M. Winnock⁹, F. Dabis⁹, J. Rockstroh¹⁰, D. Salmon¹¹, ANRS CO13 HEPAVIH and ESCMID European Study Group on Viral Hepatitis
¹Hôpital Croix Rousse, Service des Maladies Infectieuses et Tropicales, Lyon, France, ²Hôpital Saint Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France, ³Universitair Medisch Centrum Utrecht, DIGD Afdeling Interne Geneeskunde en Infectieziekten, Utrecht, Netherlands, ⁴AO Ospedale Niguarda Ca Granda, Infectious Diseases Dept, Milano, Italy, ⁵Hôpital Archet 1, Service de Médecine Interne, Nice, France, ⁶Hôpital Saint André CHU Bordeaux, Service de Medecine Interne et Maladies Infectieuses, Bordeaux, France, ⁷Hôpital Henri Mondor, Service Immunologie Clinique, Créteil, France, ⁸Hôpital Pitié Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France, ⁹INSERM U 897/ ISPED, Université Bordeaux Ségalen, Bordeaux, France, ¹⁰Oberarzt an der Medizinischen Universitätsklinik I, HIV-Immunologie-Infektiologie, Bonn-Venusberg, Germany, ¹¹Groupe Hospitalier Cochin, Service des Maladies Infectieuse et Tropicales, Paris, France

BPD2/5
Daranavir Total and Unbound Plasmatic Concentrations in HIV-HCV Coinfected Patients with Hepatic Cirrhosis Compared to HIV Monoinfected Patients
A. Curran¹, R. Martí², R.M. López³, M. Pérez¹, M. Crespo¹, M.J. Meliá², J. Burgos¹, V. Falcó¹, J. Guiu², E. Ribera¹
¹Hospital Universitari Vall d’Hebron, Infectious Diseases, Barcelona, Spain, ²Institut de Recerca Vall d’Hebron, Barcelona, Spain, ³Hospital Clinic, Barcelona, Spain

BPD2/6
APpROpriateness Score and Cost Evaluation in HIV: The APROSCE System
P. Legnazzi¹, G. Rebagliati¹, A. Perretti², S. Cima², L. Astroni¹, P. Sacchi²
¹S.C. Farmacia Fondazione Policlinico S. Matteo Pavia, Pavia, Italy, ²Dipartimento Malattie Infettive Fondazione Policlinico S. Matteo, Pavia, Italy

BPD2/7
CD38 Expression on Monocytes Marks Cells with Shorter Telomeres and Correlates with Immune Senescence in HIV Infection
M. Tarkowski¹, D. Misciagna¹, F. Strambio de Castilla¹, C. Resnati¹, C. Gervasoni², L. Ferraris¹, R. Piolini², M. Galli¹, A. Riva²
¹Università degli Studi di Milano, Milano, Italy, ²Ospedale L. Sacco, Milano, Italy

10:30 – 12:30 / Copper Hall
Parallel Session - PS8
Retention in Care / Strategies for HIV Testing

Chairs:
Karina Butler, Ireland
Dalibor Sedlacek, Czech Republic

ML1: Transition from Adolescence to Adulthood
Caroline Foster, United Kingdom

PS8/1
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study
**SCIENTIFIC PROGRAMME**
**FRIDAY, OCTOBER 18, 2013**

**LBPS8/2**

Europe-wide Increase of Early Detection of HIV-1 Infection in MSM, but Additional Strategies Are Needed for Other Risk Groups


1Gomel State Medical University, Gomel, Belarus, 2Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina, 3Ben Ari Institute of Clinical Immunology, Rehovot, Israel, 4Leicester University Hospital, Leicester, United Kingdom, 5Western General Hospital, Edinburgh, United Kingdom, 6Chelsea and Westminster Hospital, London, United Kingdom, 7Luhansk AIDS Center, Luhansk, Ukraine, 8Belarusian State Medical University, Minsk, Belarus, 9St James’s University Hospital, Leeds, United Kingdom, 10Saint-Pierre University Hospital, Brussel, Belgium, 11Hospital Universitario San Carlos, Madrid, Spain, 12Medical University of Bialystok, Department of Infectious Diseases and Bialystok, Poland, 13Karolinska University Hospital, Stockholm, Sweden, 14University Hospital of Infectious Diseases, Zagreb, Croatia, 15The Newcastle Upon Tyne Hospital, Newcastle, United Kingdom, 16Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, 17Centre Hospitalier de Tourcoing, Tourcoing, France, 18University of Catania, ARNAS Garibaldi, Catania, Italy, 19Hospital Curry Cabral, Lisbon, Portugal, 20University Hospital Innsbruck, Innsbruck, Austria, 21San Paolo Hospital, Milan, Italy, 22Roskilde Hospital, Roskilde, Denmark, 23University College London, London, United Kingdom, 24Hospital Clinic de Barcelona, Barcelona, Spain, 25University of Bonn, Department of Internal Medicine, Bonn, Germany, 26Hospital Bichat Claude Bernard, Paris, France, 27Inserm U 738, ATIP/AVENIR Team, Paris, France, 28Copenhagen HIV Programme, Copenhagen, Denmark

**PS8/4**

Factors Influencing Linkage to Care After HIV Diagnosis in Central Poland – Preliminary Results from Test and Keep in Care (TAK) project


1Fundacja Edukacji Społecznej (FES), Warsaw, Poland, 2Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland, 3Hospital for Infectious Diseases, Central Analytical Laboratory, Warsaw, Poland, 4Medical University of Warsaw, Department of Hepatology and Acquired Immunodeficiencies, Warsaw, Poland, 5Medical University of Warsaw, Department for Adult’s Infectious Diseases, Warsaw, Poland

**PS8/5**

Cascade of HIV Care in the Netherlands from 2002 to 2013

E.A.N. Engelhard, C. Smit, A.I. van Sighem, P. Reiss, K. Brinkman, S.E. Geerlings, on behalf of the Q-HIV and the ATHENA National Observational Cohort Study Groups

1Division of Infectious Diseases, Academic Medical Centre of the University of
Amsterdam, Amsterdam, Netherlands, 2Stichting HIV Monitoring, Amsterdam, Netherlands, 3Dept of Global Health, Amsterdam Academic Medical Centre of the University of Amsterdam, Institute for Global Health and Development, Amsterdam, Netherlands, 4Onze Lieve Vrouwe Gasthuis, Internal Medicine, Amsterdam, Netherlands

PS8/6
‘Connect Email’: 4 Years experience of an Email Clinic in an Outpatient HIV Setting
J. Whetham1, C. Hendrickx1, M. Fisher1
1Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom

ML2: Issues in Migrant Populations
Julia del Amo, Spain

13:00 – 14:00 / Bozar (Plenary Hall)

Special Session
EACS HIV Treatment Guideline: What’s New?

Chairs:
Manuel Battegay, Switzerland
Margaret Johnson, United Kingdom

Panel:
Georg Behrens, Germany
Nathan Clumeck, Belgium
Jürgen Rockstroh, Germany

14:00 – 16:00 / Bozar (Plenary Hall)

Parallel Session - PS9
HIV and Hepatitis Co-Infection

Chairs:
Sanjay Bhagani, United Kingdom
Andrzej Horban, Poland

ML1: Hepatitis E: an Emerging Problem in HIV?
Sven Pischke, Germany

PS9/1
Substantial Rates of Acute Hepatitis C Reinfection in European HIV-positive Patients
P. Ingiliz1, T.C. Martin2, C. Boesecke3, S. Mauss4, B.A. Payer5, M. Mandorfer6, A. Baumgarten1, H.-J. Stellbrink6, S. Bhagani7, J.K. Rockstroh5, M. Nelson6, and the NEAT Study Group
1Medical Center for Infectious Diseases, Berlin, Germany, 2Chelsea and Westminster Hospital, HIV Department, London, United Kingdom, 3University of Bonn, Medical Department, Bonn, Germany, 4Center for HIV and Hepatogastroenterology, Duesseldorf, Germany, 5Vienna Medical University, Vienna, Austria, 6ICH Study Center, Hamburg, Germany, 7Royal Free Hospital, London, United Kingdom

PS9/2
Performance of Boceprevir (BOC) or Telaprevir (TLV) in Triple Therapy with Peginterferon (pegIFN) and Ribavirin (RBV) in Routine Clinical Practice
P. Barreiro1, B. Cornelli1, I. Maida1, A. Aguilera1, E. Vispo1, J.V. Fernández-Montero1, P. Labarga1, V. Soriano1
1Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

PS9/3
Efficacy of DAAs Based HCV Triple Therapy in HIV-HCV Co-infected Patients: Interim 24-week Results
1Bonn University Hospital, Department of Medicine I, Bonn, Germany, 2Matei Bals National Institute of Infectious Diseases, Adults III Department, Bucharest, Romania, 3Hospital Universitario de Valme, Unit of Infectious Diseases and Microbiology, Seville, Spain, 4Maimonides Institute for Biomedical Research (IMIBIC), Hospital Universitario Reina Sofia, Unit of Infectious Diseases and Microbiology, Cordoba, Spain, 5Hospital Universitario de la Princesa, Unit of Infectious Diseases, Madrid, Spain, 6Frankfurt University Hospital, Department of Medicine II, Frankfurt, Germany, 7Medical Center for Infectious Diseases, Berlin, Germany, 8Hospital Universitario Virgen de la Victoria, Unit of Infectious Diseases, Malaga, Spain, 9Infektiologikum, Frankfurt, Germany, 10Essen University Hospital, Department of Dermatology and Venerology, Essen, Germany, 11Medizinische Hochschule, Klinik fur Immunologie und Rheumatologie, Hannover, Germany, 12Hospitales Universitarios Virgen del Rocio, Unit of Infectious Diseases, Seville, Spain, 13Praxisgemeinschaft, Stuttgart, Germany, 14Infektiions Medizinisches Centrum, Hamburg, Germany, 15Center for HIV and Hepatogastroenterology,
Düsseldorf, Germany, Hospital Regional Carlos Haya, Service of Infectious Diseases, Malaga, Spain, Hospital Torrecárdenas, Internal Medicine Department, Almeria, Spain, Gemeinschaftspraxis Gotenring, Cologne, Germany, Hospital Juan Ramón Jiménez, Internal Medicine Service, Huelva, Spain, Ludwig-Maximilians-University, Medizinische Poliklinik, Munich, Germany

PS9/4
Different Frequency of Naturally Anti-HCV Protease Inhibitors Resistant Mutants in Genotype 1 Subtypes 1a, 1b and 1c
S. Bagaglio¹, E. Messina¹, A. Smacchia¹, M. Merli¹, H. Hasson¹, A. Lazzarin¹, C. Uberti-Foppa¹, G. Morsica¹
¹Scientific Institute Ospedale San Raffaele, Infectious Diseases Dept., Milan, Italy

LBPS9/5
Simeprevir (TMC435) plus Peginterferon/Ribavirin in Patients Co-infected with HCV genotype-1 and HIV-1: Primary Analysis of the C212 Study
D. Dieterich¹, J. Rockstroh², C. Orkin³, F. Gutiérrez⁴, M.B. Klein⁵, J. Reynes⁶, W. Jessner⁷, A. Jenkins⁸, O. Lenz⁹, S. Ouwerkerk-Mahadevan⁹, M. Peeters⁹, G. De La Rosa⁹, L. Tambuyzer⁹, M. Beumont-Mauviel⁹
¹Icahn School of Medicine at Mount Sinai, New York, United States, ²Mediz. Universitätsklinik-Immunologische Ambulanz, Bonn, Germany, ³Royal London Hospital, London, United Kingdom, ⁴Hospital General de Eiche and Universidad Miguel Hernández, Alicante, Spain, ⁵McGill University Health Centre, Montreal, Canada, ⁶Hôpital Guî De Chauliac, Montpellier, France, ⁷Janssen Infectious Diseases BVBA, Beerse, Belgium, ⁸Janssen Research & Development, Raritan, United States, ⁹Janssen Global Services, Titusville, United States

LBPS9/6
Simeprevir with Peginterferon/Ribavirin in Treatment-naïve or -experienced Patients with Chronic HCV Genotype 4 Infection: A Phase III Study
C. Moreno¹, C. Hezode², P. Marcellin³, S. Bourgeois⁴, S. Francque⁵, D. Samuel⁶, F. Zoulim⁷, J.-D. Grange⁸, W. Jessner⁹, O. Lenz⁹, S. Ouwerkerk-Mahadevan⁹, M. Peeters⁹, M. Beumont-Mauviel⁹
¹ULB Hôpital Erasme, Brussels, Belgium, ²Hôpital Henri Mondor, Créteil, France, ³Hôpital Beaujon, Clichy, France, ⁴ZNA Campus Stuivenberg, Antwerp, Belgium, ⁵UZ Antwerpen, Antwerp, Belgium, ⁶Hôpital Paul Brousse, Villejuif, France, ⁷Hôpital de la Croix Rousse, Lyon, France, ⁸Hôpital Tenon, Paris, France, ⁹Janssen Infectious Diseases BVBA, Beerse, Belgium

PS9/7
STARTVerso 4 Phase III Trial of Faldaprevir Once-daily Plus Peg Interferon Alfa-2a and Ribavirin (PR) in Patients with HIV and HCV Genotype 1 Coinfection: End of Treatment Response (ETR)
¹University of Bonn, Bonn, Germany, ²Chelsea and Westminster Hospital, London, United Kingdom, ³Hospital Carlos III, Madrid, Spain, ⁴EPIMED, Vivantes Auguste-Viktoria Hospital, Berlin, Germany, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Royal Free Hospital, London, United Kingdom, ⁷Hospital Clinic, Barcelona, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁹AO Ospedale Niguarda Cà Granda, Milan, Italy, ¹⁰Medizinisches Infektiologiezentrums Berlin (MIB), Berlin, Germany, ¹¹Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland, ¹²UT Southwestern Medical Center, Dallas, United States, ¹³Weill Cornell Medical College, New York, United States, ¹⁴Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States, ¹⁵Boehringer Ingelheim España S.A, Barcelona, Spain, ¹⁶Mount Sinai School of Medicine, New York, United States

14:00 – 16:00 / Gold Hall
Parallel Session - PS10
EACS/ESCmID Joint Session on Tuberculosis Co-Infection
Chairs:
Stephen Lawn, United Kingdom
Jose Miro, Spain

ML1: TB Diagnosis in HIV Infected Patients: From IGRAs to GenXpert
Emmanuelle Cambau, France

PS10/1
Systematic Screening and Treatment Prophylaxis for Tuberculosis in HIV Patients in a High Income Setting in 2013: Is it Useful?
U. Maniewski¹, M. Delforge¹, M.-C. Payen¹, S. De Wit¹
¹CHU Saint-Pierre, Infectious Diseases, Brussels, Belgium
ML2: MDR/XDR-TB Treatment – What Are the Role of the New Drugs
Frank v. Leth, Netherlands

PS10/2
Nutritional Supplementation Increases Rifampicin Exposure among HIV Co-infected Tuberculosis Patients
J. Kidola1,2, P. Denti3, E. Chigutsa3, D. Faurholt-Jepsen4, G. Pray God1, N. Range5, C.M. Hagen6, M. Christiansen6, J. Changalucha1, H. McIlrrome3, H. Friis4, A.B. Andersen6
1National Institute for Medical Research, Mwanza Centre, Mwanza, Tanzania, United Republic of, 2Odense University Hospital, Dept Infectious Diseases, Odense, Denmark, 3University of Cape Town, Division of Clinical Pharmacology, Cape Town, South Africa, 4University of Copenhagen, Dept of Nutrition, Exercise and Sports, Copenhagen, Denmark, 5National Institute for Medical Research, Muhimbili Research Centre, Dar es Salaam, Tanzania, United Republic of, 6Statens Serum Institut, Dept of Clinical Biochemistry, Immunology and Genetics, Copenhagen, Denmark

ML3: TB in Eastern Europe
Daria Podlekareva, Denmark

PS10/3
Organisation and Delivery of Healthcare for HIV/TB Coinfected Patients in Europe
M. Mansfeld1, A. Skrahina2, A.M. Panteeve3, J.M. Miro4, I. Zeltina5, S. Tetradow6, A. Mocroft5, A. Grzeszczuk8, L. Shepherd1, N. Bolokadze9, J.D. Lundgren1,10, A. Matteelli11, F.A. Post12, O. Kirk1,10, D.N. Podlekareva1, The TB:HIV Study in EuroCoord
1Copenhagen HIV Programme, Rigshospitalet, Copenhagen University Hospital and University of Copenhagen, Copenhagen, Denmark, 2Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus, 3TB Hospital #2, St. Petersburg, Russian Federation, 4University of Barcelona, Hospital Clinic - IDIBAPS, Barcelona, Spain, 5Infectology Centre of Latvia, Riga, Latvia, 6Dr. Victor Babes’ Hospital for Infectious and Tropical Diseases, Bucharest, Romania, 7University College London, Royal Free Campus, London, United Kingdom, 8Medical University of Bialystok, Bialystok, Poland, 9Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia, 10Copenhagen University Hospital/Rigshospitalet, Dept of Infectious Diseases, Copenhagen, Denmark, 11Istituto Malattie Infettive e Tropicali Università degli Studi di Brescia, Brescia, Italy, 12King’s College London School of Medicine, London, United Kingdom

PS10/4
Evaluation of Clinical Profile and Evolution of Tuberculosis among HIV Infected and Uninfected Children
F. Kitetele1, J. Lusiama2, P. Lelo1, C. Akele3
1Kalembelme Pediatric Hospital, Infectious Diseases Unit, Kinshasa, Congo, 2Health Public School of Kinshasa, Kinshasa, Congo, the Democratic Republic of the, 3Kalembelme Pediatric Hospital, Kinshasa, Congo, the Democratic Republic of the

ML4: What’s New in the Management of HIV/TB?
Anton Pozniak, United Kingdom

14:00 – 16:00 / Copper Hall

Parallel Session - PS11
Sex, Drugs and Stigma

Chairs:
Marie Laga, Belgium
Jean-Michel Molina, France

ML1: Stigma Still Relevant in 2013
Deniz Gökengin, Turkey

PS11/1
Reasons for Not Starting Antiretroviral Therapy: A Multinational Survey among Patients and their Physicians
J. Fehr1, D. Nicca2, J.-C. Goffard3, D.H.-U. Haerry4, R. Diazaraque5, B. Ledergerber6
1University Hospital Zurich, University of Zurich, Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland, 2Cantonal Hospital St. Gallen, Division of Infectious Diseases and Hospital Hygiene, St. Gallen, Switzerland, 3University Hospital Erasme, AIDS Reference Centre, Bruxelles, Belgium, 4Positive Council, Zurich, Switzerland, 5Gilead Sciences Ltd, Medical Affairs, Uxbridge, United Kingdom

PS11/2
Ability to Work of HIV-infected Individuals after Starting cART: The Swiss HIV Cohort Study
L. Elzi1, A. Patzen2, A. Conen3, J. Fehr4, H. Furrer5, M. Cavassini5, A. Calmy7, P. Schmid8, E. Bernasconi9, M. Battegay1
1University Hospital Zurich, University of Zurich, Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland, 2Cantonal Hospital St. Gallen, Division of Infectious Diseases and Hospital Hygiene, St. Gallen, Switzerland, 3University Hospital Erasme, AIDS Reference Centre, Bruxelles, Belgium, 4Positive Council, Zurich, Switzerland, 5Gilead Sciences Ltd, Medical Affairs, Uxbridge, United Kingdom
**PS11/3**

Recreational Drug Use and High Risk Sexual Behaviour among HIV-diagnosed Men who Have Sex with Men (MSM) in the UK: Results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study


1University College London, London, United Kingdom, 2Royal Free Hampstead NHS Trust, London, United Kingdom, 3Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom, 4Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 5Homerton University Hospital NHS Trust, London, United Kingdom, 6Barts Health NHS Trust, London, United Kingdom, 7East Sussex Health Care NHS Trust, Eastbourne, United Kingdom, 8HIV i-Base, London, United Kingdom, 9City University, London, United Kingdom, 10London School of Hygiene and Tropical Medicine, London, United Kingdom, 11University of Liverpool, Liverpool, United Kingdom, 12University of Colorado, Colorado, United States

**PS11/4**

An Outbreak of Primary HIV Infection among Injecting Drug Users in Tel Aviv, Israel Associated with Changes in the Illicit Drug Use Practices

E. Katchman1, M. Savyon2, D. Chemtob3, B. Avidor4, O. Mor5, A. Wasserman1, I. Zeldis4, S. Girshengorn4, Z. Amitai2, R. Sheffer2, R. Ben-Ami1, D. Turner1

1Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Infectious Diseases Unit, Tel Aviv, Israel, 2Ministry of Health, Tel Aviv District Health Office, Tel Aviv, Israel, 3Ministry of Health, Tuberculosis and AIDS

**PS11/5**

Effective Antiretroviral Therapy: Impact on the Criminalization of HIV Exposure

D. Glejser1

1Groupe Sida Genève, Genève, Switzerland

**PS11/6**

HIV/AIDS Stigma and Discrimination in Health Care Sector in Belarus

V. Ilyenkova1, S. Kunitskaya2, I. Eramova3

1World Health Organization Regional Office for Europe, WHO Country Office in Belarus, Communicable Diseases, Minsk, Belarus, 2Belarusian State Medical University, Public Health, Minsk, Belarus, 3World Health Organization Regional Office for Europe, Copenhagen, Denmark

**ML2:** Self-Stigma: An Unspoken World of Unspoken Things

Nadine Ferris France, Ireland
08:00 – 08:30 / Gold Hall

**Plenary Session - PL5**
HIV and Quality of Care in Europe

**Chairs:**
Jose Arribas, Spain
Damir Bilkumukhametov, Russian Federation

HIV and Quality of Care in Europe
Jens Lundgren, Denmark

08:30 – 09:00 / Gold Hall

**Plenary Session - PL6**
Antiretroviral Therapy – New Strategies or New Drugs?

**Chairs:**
Jose Arribas, Spain
Damir Bilkumukhametov, Russian Federation

Antiretroviral Therapy – New Strategies or New Drugs?
François Raffi, France

09:00 – 10:30 / Gold Hall

**Special Session**
Clinical Case Session

**Chairs:**
Hans-Jakob Furrer, Switzerland
Brian Gazzard, United Kingdom

**Experts:**
Georg Behrens, Germany
Bonaventura Clotet, Spain
Nina Friis-Møller, Denmark
Itzhak Levy, Israel
Stefano Rusconi, Italy

**Presenters:**
Giulia Marchetti, Italy
Cristiana Oprea, Romania
Roger Paredes, Spain
Dominic Rowley, Ireland

10:30 – 12:00 / Gold Hall

**Special Session**
ART for Prevention - Roll it Out?

**Chairs:**
Dominique Costagliola, France
David Haerry, Switzerland

Clinical Perspective
Bernard Hirschel, Switzerland

Community Perspective
Gus Cairns, United Kingdom

Scientific Perspective
Sheena McCormack, United Kingdom

Economical Perspective
Yazdan Yazdanpanah, France

Panel:
Bernard Hirschel, Switzerland
Gus Cairns, United Kingdom
Sheena McCormack, United Kingdom
Yazdan Yazdanpanah, France

12:00 – 12:30 / Gold Hall

**Closing**

Manuel Battegay, Switzerland
Nathan Clumeck, Belgium
José Gatell, Spain
14th EUROPEAN AIDS CONFERENCE

SCHEDULE AT A GLANCE

EACS PRE-EDUCATIONAL COURSE

SCIENTIFIC PROGRAMME

POSTERS

SATELLITE SYMPOSIA

CONFERENCE VENUE

EXHIBITORS AND EXHIBITION FLOOR PLAN

EACS 25TH ANNIVERSARY EVENT

GENERAL INFORMATION A - Z

BRUSSELS

IMPORTANT ADDRESSES
The content of Satellite Symposia is the responsibility of the organising company.

**Wednesday, October 16, 2013**
**11:30 – 13:00 / Gold Hall**

**Non-Commercial**

**CHAARM**
New HIV Prevention Strategies: The Future of Microbicides

Chair:
Gus Cairns, United Kingdom

**Where We Are Globally in Microbicide Research**
Sheena McCormack, United Kingdom

**The Work of the CHAARM European Microbicides Research Consortium**
Guido Vanham, Belgium

**The Delicate Balance Between Efficacy and Toxicity: The Effect of Microbicides on the Local Vaginal or Rectal Environment**
Janneke van de Wijgert, United Kingdom

**What People Say They Want From a Microbicide and How They Could be Marketed**
Harriet Langanke, Germany

**The EU Commitment for Research on HIV Prevention in Europe**
Alessandra Martini, Belgium

**Discussion**
Gus Cairns, United Kingdom

---

**Bristol-Myers Squibb**
HIV Cure on Trial: Hype or Hope?
The symposium will be a debate structured as a ‘courtroom drama’. The symposium chair will take the role of judge, the other faculty will be opposing lawyers and expert witnesses, and the audience will be the jury.

**Judge’s opening remarks**
Christine Katlama, France

**The evidence**

**Defence: Cure is possible in virology**
Giuseppe Pantaleo, Switzerland

**Defence: HCV as virology cure success**
Carlo Federico Perno, Italy

**Prosecution: Biological challenges of HIV**
José Alcami, Spain

**Prosecution: Limited research success**
Georg Behrens, Germany

**Defence closing argument**
Giuseppe Pantaleo, Switzerland

**Prosecution closing argument**
Georg Behrens, Germany

**Cross-examination (All)**

Q&A / discussion session
Christine Katlama, France

**Verdict and summary**
Christine Katlama, France
Wednesday, October 16, 2013
15:30 – 17:00 / Gold Hall

**AbbVie**
The Evolving HIV Treatment Paradigm

Chair:
Pedro Cahn, Argentina

History and Evolution of HIV Treatment
Pedro Cahn, Argentina

The EARNEST Study
Nicholas Paton, Singapore

The Second Line Study
David Cooper, Australia

Two-Drug Therapy Trials
François Raffi, France

Panel & Audience Discussion

---

Thursday, October 17, 2013
07:15 – 08:45 / Gold Hall

**MSD**
Integrase Inhibitors – A Retrospective and a Look Ahead

Chair:
Nathan Clumeck, Belgium

Welcome and Opening Remarks
Nathan Clumeck, Belgium

Raltegravir: What Have We Learned in the Last 5 Years?
Christine Katlama, France

Multiple Integrase Inhibitors, Multiple Patient Types
Graeme Moyle, United Kingdom

Discovery and Evolution of Integrase Inhibitors: Hope for the Future
Mike Miller, United States

Discussion

Closing Remarks
Nathan Clumeck, Belgium
Gilead
Rooted in Research: The Future of HIV

Chair:
Jürgen Rockstroh, Germany
Laura Waters, United Kingdom

Branching out: New Perspectives of the HIV Epidemic
Anna Mia Ekström, Sweden

How Our Roots Determine the Growth for the Future
Pierre Corbeau, France

Rooted in Research: Is a Cure on the Horizon?
Calvin Cohen, United States

The First Shoots:
Antiretroviral Treatment, is Universal Coverage Possible?
Anna Mia Ekström, Sweden

ViiV Healthcare
Just Another HIV Symposium? Think Again...

Chair:
Brian Gazzard, United Kingdom

Beyond the Evidence Base: Overview of Current Picture for Patients with HIV Focusing on Life Expectancy, Quality of Life and Patient Satisfaction
Brian Gazzard, United Kingdom

My HIV. My Life. A Personal Perspective (video)
Series of Patients Talking About the Impact HIV Has on All Areas of Their Lives
Patient Videos

The Importance of Being Involved: Highlighting the Need for Patients to be Involved in the Decision-Making Process
Sandra Van den Eynde, Belgium

Are We Prepared to Manage HIV as a Chronic Condition? Overview of a New Approach to Patient Centered Care and Why it is Needed
Andrew Miles, United Kingdom

Collaborative Care in Action: Creating a Decision Aid in Real Time
Interactive Section Involving the Audience and Supported by a Panel Discussion with the Aim of Agreeing Criteria to Include in an HIV Decision Aid
Facilitated by Andrew Miles, United Kingdom
Panel:
Brian Gazzard, United Kingdom; Sandra Van den Eynde, Belgium; Jürgen Rockstroh, Germany; Gilles Pialoux, France

Meeting Summary and Close
Brian Gazzard, United Kingdom
Bristol-Myers Squibb
The Evolution of the Standard of Care:
The Changing Face of HIV Treatments

Chair:
Linos Vandekerckhove, Belgium
Anton Pozniak, United Kingdom

Introduction – What is your standard of care?
Examining current perceptions
Linos Vandekerckhove, Belgium

Tried and tested? Understanding the Wealth of Data for the Standard of Care
Hans-Jürgen Stellbrink, Germany

Managing HIV: How Standard is Your Care?
Paddy Mallon, Ireland

The Standard of Care Made Simple: Can One Size fit All?
Santiago Moreno, Spain

Panel Discussion
Facilitated by
Anton Pozniak, United Kingdom

Close and Summary
Anton Pozniak, United Kingdom

Janssen
The HIV Debate:
What's the Best Approach to Personalise Treatment?

Chair:
Hans-Jürgen Stellbrink, Germany

Welcome and Outline
Hans-Jürgen Stellbrink, Germany

Debate 1: Controversies in Guidelines
Anton Pozniak, United Kingdom; Jose Arribas, Spain

Debate 2: Is Treatment Simplification Fit for All Patients?
Jose Arribas, Spain; Diego Ripamonti, Italy

Debate 3: Treating Long-Term or Short-Term?
Diego Ripamonti, Italy; Anton Pozniak, United Kingdom

Conclusions and Any Questions
Hans-Jürgen Stellbrink, Germany